The factors such as rising use of organ-on-a-chip in early detection of drug toxicity, increasing demand for personalized medicine, emergence of OOC as an alternative to animal testing, the significant increase in research funding and venture capital investments for the development of different types of organ-on-a-chips are driving the market growth.
The factors such as increasing instance of chronic diseases, outbreak of new infectious diseases, technological innovations, increased need of personalized medicine, biomarker discovery and crop improvement research are driving the market.
The factors such as increasing demand for early detection of chronic diseases, increasing demand for genetic and molecular testing, expiry of PCR patents of major players, increased investments in the field of companion diagnostics using PCR are driving the market.
Live-cell imaging, single-cell analysis, and high content screening (HCS) are few technologies where individual cells are analyzed for in their natural states are gaining prominence in the cell analysis market.
Animals in research are essential for the development of new and more effective methods for diagnosis and treatment of diseases and to mandatorily submit preclinical pharmacological, toxicological and pharmacokinetic findings.
A decade has gone, since the first human genome has been sequenced and sequencing technology has come a long way from the time of introduction as Next Generation Sequencing (NGS) has revolutionized the way the human genomes are being sequenced now a days.
Cell expansion process plays a key role in therapeutic development, drug screening and core research. It is used for improving the outcome of transplantation and diseases such as rheumatoid arthritis and diabetes.